Kura Oncology, Inc. (FRA:KUR)
Germany
· Delayed Price · Currency is EUR 10.13
+0.04 (0.40%)
At close: Dec 5, 2025
Kura Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 104.03 | 53.88 | - | - | - | - | Upgrade
|
| Cost of Revenue | 153.38 | 155.35 | - | - | - | - | Upgrade
|
| Gross Profit | -49.35 | -101.46 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 104.91 | 77.11 | 50.57 | 47.05 | 46.54 | 31.5 | Upgrade
|
| Research & Development | 85.55 | 14.62 | 115.24 | 92.81 | 84.72 | 60.4 | Upgrade
|
| Operating Expenses | 190.47 | 91.73 | 165.8 | 139.87 | 131.26 | 91.9 | Upgrade
|
| Operating Income | -239.82 | -193.2 | -165.8 | -139.87 | -131.26 | -91.9 | Upgrade
|
| Interest Expense | -1.57 | -1.62 | -1.55 | -0.23 | -0.41 | -0.58 | Upgrade
|
| Interest & Investment Income | 13.61 | 9.71 | 5.3 | 5.86 | 5.6 | 3.26 | Upgrade
|
| EBT Excluding Unusual Items | -227.78 | -185.11 | -162.05 | -134.23 | -126.08 | -89.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.14 | 13.14 | 9.42 | -1.61 | -4.39 | -0.41 | Upgrade
|
| Pretax Income | -214.64 | -171.97 | -152.63 | -135.84 | -130.47 | -89.63 | Upgrade
|
| Income Tax Expense | 2.24 | 2.02 | - | - | - | - | Upgrade
|
| Net Income | -216.88 | -173.98 | -152.63 | -135.84 | -130.47 | -89.63 | Upgrade
|
| Net Income to Common | -216.88 | -173.98 | -152.63 | -135.84 | -130.47 | -89.63 | Upgrade
|
| Shares Outstanding (Basic) | 87 | 86 | 73 | 67 | 66 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 87 | 86 | 73 | 67 | 66 | 53 | Upgrade
|
| Shares Change (YoY) | 4.45% | 17.66% | 9.31% | 0.96% | 25.01% | 26.54% | Upgrade
|
| EPS (Basic) | -2.48 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | Upgrade
|
| EPS (Diluted) | -2.48 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | Upgrade
|
| Free Cash Flow | 83.11 | 133.85 | -124.99 | -110.69 | -105.7 | -72 | Upgrade
|
| Free Cash Flow Per Share | 0.95 | 1.55 | -1.71 | -1.65 | -1.59 | -1.36 | Upgrade
|
| Gross Margin | -47.44% | -188.30% | - | - | - | - | Upgrade
|
| Operating Margin | -230.53% | -358.54% | - | - | - | - | Upgrade
|
| Profit Margin | -208.48% | -322.89% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 79.89% | 248.40% | - | - | - | - | Upgrade
|
| EBITDA | -238.99 | -192.35 | -164.96 | -139.11 | -130.7 | -91.71 | Upgrade
|
| D&A For EBITDA | 0.83 | 0.85 | 0.85 | 0.76 | 0.56 | 0.19 | Upgrade
|
| EBIT | -239.82 | -193.2 | -165.8 | -139.87 | -131.26 | -91.9 | Upgrade
|
| Revenue as Reported | 104.03 | 53.88 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.